Fennec reports Q1 EPS (4c), consensus (9c)

Reports Q1 revenue $8.75M, consensus $8.18M. “In the first quarter, we sharpened our strategic focus and achieved sustainable growth across key PEDMARK accounts. Importantly, our Fennec (FENC) HEARS patient support program has been newly revamped to ensure growth with a seamless, supportive experience for both providers and adolescent and young adult, or AYA, cancer patients at every step of the PEDMARK journey,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. “Looking ahead, we are energized by the momentum that we are building and remain committed to executional excellence. We are deepening our relationships with key accounts and expanding adoption with new and existing customers. With this strong foundation and forward vision, we are confident in our ability to drive value for patients, providers, and shareholders.”